Pradžia › Osteosarkoma › Masčusetsas
Osteosarkoma klinikiniai tyrimai Masčusetsas
9 tyrimai dėl Osteosarkoma ieško dalyvių vietose Masčusetsas.
Miestai Masčusetsas
Oficialus tyrimo tekstas (anglų kalba)
Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor
- Dana-Farber Cancer Institute, Boston
Renkami dalyviai2 fazė
Amžius nuo 12 iki 39 · Visoms lytims · Atnaujinta 2026-09-29 · NCT04616560Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
Renkami dalyviai3 fazė
Iki 50 metų · Visoms lytims · Atnaujinta 2026-08-25 · NCT05235165Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Dana-Farber Cancer Institute, Boston
Renkami dalyviai1/2 fazė
12 Months – 30 Years · Visoms lytims · Atnaujinta 2026-08-25 · NCT04851119SPEARHEAD-3 Pediatric Study
- Dana Farber Cancer Institute, Boston
Renkami dalyviai1/2 fazė
Amžius nuo 2 iki 21 · Visoms lytims · Atnaujinta 2026-08-11 · NCT05642455NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
- Dana Farber Cancer Institute, Boston
Renkami dalyviai1/2 fazė
Iki 30 metų · Visoms lytims · Atnaujinta 2026-08-03 · NCT06239272Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
- Dana-Farber Cancer Institute, Boston
Renkami dalyviaiStebimasis tyrimas
Visi amžiai · Visoms lytims · Atnaujinta 2026-05-18 · NCT01790152Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy)
- Dana Farber Cancer Institute, Boston
Renkami dalyviai1/2 fazė
Amžius 12 ir vyresni · Visoms lytims · Atnaujinta 2026-05-01 · NCT07357519Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study
- Dana-Farber Cancer Institute, Boston
Renkami dalyviai2 fazė
Amžius 12 ir vyresni · Visoms lytims · Atnaujinta 2026-04-17 · NCT05019703Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas
- Boston Children's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
- Brigham and Women's Hospital, Boston
Renkami dalyviai1/2 fazė
Amžius nuo 12 iki 49 · Visoms lytims · Atnaujinta 2026-02-19 · NCT06709495Iš ClinicalTrials.gov, duomenys gauti 2026-10-04. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.